Colorectal cancer (CRC) accounts for over 600 000 deaths annually worldwide. The current study aims to evaluate the value of proto-oncogene PIM1 as a therapeutic target in CRC and investigate the anticancer activity of hispidulin, a naturally occurring phenolic flavonoid compound, against CRC. Immunohistochemistry analysis showed that PIM1 was upregulated in CRC tissue. The role of PIM1 as an oncogene was evidenced by the fact that PIM1 knockdown inhibits cell growth, induces apoptosis, and suppresses invasion. Our results showed that hispidulin exerts antitumor activity in CRC through inhibiting the expression of PIM1. Moreover, our findings revealed that hispidulin downregulated the expression of PIM1 by inhibiting JAK2/ STAT3 signaling by generating reactive oxygen species. Furthermore, our in vivo studies showed that hispidulin can significantly inhibit tumor growth and metastasis in CRC. Collectively, our results provide an experimental basis for trialing hispidulin in CRC treatment. PIM1 can be considered a potential therapeutic target in CRC. pancreatic ductal carcinoma, 10 and non-small-cell lung cancer. 11 With regards to CRC, a total PIM1 score that reflects the expression of PIM1 in tumors, tumor stroma, and tumor-adjacent mucosa has been found to correlate with disease stages, and can be considered a Abbreviations: CRC, colorectal cancer; DCFH-DA, 2 0 ,7,-dichlorofluorescein-diacetate; IHC, immunohistochemistry; IL, interleukin; NAC, N-acetylcysteine; NF-jB, nuclear factor-jB; PARP, poly(ADP-ribose) polymerase; PIM1, provirus integration site for Moloney murine leukemia virus; ROS, reactive oxygen species; STAT, signal transducer and activator of transcription.
useful prognostic marker of CRC. 12 However, the value of PIM1 as a therapeutic target remains to be evaluated.
Flavonoids have been reported to provide health benefits for humans. Hispidulin (4 0 ,5,7-trihydroxy-6-methoxyflavone), is a kind of phenolic flavonoid compound isolated mainly from Salvia involucrata, a medicinal plant traditionally used in oriental medicine. 13 In recent years, accumulating evidence has revealed the pleiotropic effects of hispidulin, including antioxidant, anti-inflammatory, neuroprotective, antithrombotic, anti-osteoporotic, and anti-epileptic activities. [14] [15] [16] [17] [18] [19] [20] More importantly, many in vivo and in vitro studies have reported that hispidulin shows its antitumor effects against a variety of solid tumors and hematological malignancies, including acute myeloid leukemia, hepatocellular carcinoma, colon carcinoma, gallbladder cancer, and renal cell carcinoma. [21] [22] [23] [24] [25] Our previous studies have identified that hispidulin inhibited the growth and metastasis of cells by regulating the activity of sphingosine kinase 1 in renal cell carcinoma. 22 However, its role in CRC and its underlying mechanisms remain elusive.
In the present study, the suppressive role of hispidulin on CRC growth and metastasis was investigated in vitro and in vivo. Moreover, our study was aimed at examining what role PIM1 plays in the antitumor effect of hispidulin against CRC, and exploring the pathways responsible for the regulating effect of hispidulin on PIM1.
| MATERIALS AND METHODS

| Clinical samples
This study was given official approval by the ethics committee of Qingdao University (Qingdao, China) and written consent forms were approved by all patients. A total of 63 patients with CRC who underwent surgical procedures between June 2014 and February 2016 were recruited in this study. Colorectal cancer tissue and adjacent non-cancer tissue were sampled and stored at À80°C. Diagnosis and staging were carried out by 2 independent senior oncologists blinded to the data. The level of PIM1 in tissue samples was determined by an IHC assay. The primary antibodies used for the IHC assay were as follows: polyclonal antibodies against PIM1 and Ki-67 (Abcam, Shanghai, China) and polyclonal antibodies against cleaved caspase-3 (Cell Signaling Technology, Danvers, MA, USA). The expression levels of marker molecules were quantified as previously described. 26 To explore the correlation between PIM1 expression and clinicopathological characteristics, the tissue samples were allocated into 2 groups: (i) <25% positive cells defined as (À); and (ii) ≥75% positive cells defined as (+).
| Cell culture
Human CRC cell lines HT29 and SW480 were purchased from the 
| Flow cytometry analysis
Colorectal cancer cells were harvested following treatment, and an apoptosis kit (BD Pharmingen, Franklin Lakes, NJ, USA) was used to stain cells with annexin V-phycoerythrin and propidium iodide. Cell apoptosis was determined using a flow cytometer (Thermo Fisher Scientific, Shanghai). 
| Transwell invasion assay
| PIM1 knockdown
Two siRNAs were synthesized by GenePharma (Shanghai, China) as previously described. 27 The cording strands of the siRNAs were CCAUGGAAGUGGUCCUGCUGAAGAA (Pim1-1) and GUAU-GAUAUGGUGUGUGGAGAUAUU (Pim1-2). Non-silencing scramble siRNA was purchased from GenePharma. The siRNA sequence that showed better knockdown efficiency was used in the experiment.
The PIM1 targeting the siRNA and scramble sequence as a control were respectively inserted into the plasmid vector pEGFP-N1
(Wuhan Miaoling Bioscience and Technology, Wuhan, China). Western blot analysis measured the expression of PIM1 48 hours after transfection.
| PIM1 overexpression
Empty vectors were carried into CRC cells by Lipofectamine 3000 reagent (Invitrogen, Grand Island, NY, USA) in accordance with the manufacturer's instructions. As previously described, plasmid vector pEGFP-N1 (Wuhan Miaoling Bioscience and Technology) was used to construct the PIM1 overexpressing vector. 28 The expression of PIM1 48 hours after transfection was measured by Western blot analysis.
| In vivo tumor growth model
The Institutional Animal Care and Use Committee at Qingdao
University approved all animal experiments in this study. Eightweek-old male athymic BALB/c nu/nu mice were given sterile food and water in pathogen-free conditions. The mice were injected with using IHC staining and measured using the TUNEL assay according to the protocols described in our previous work. 
| Pulmonary metastasis animal model
Mice were injected with HT29 cells (1 9 10 6 ) in 0.1 mL saline into the tail vein, and killed after a 12-week inoculation period. Hematoxylin-eosin was used to stain consecutive sections of the whole lung. All metastatic lesions in the lungs of the mice were assessed and counted to evaluate the role of hispidulin on the pulmonary metastasis of CRC.
| Statistical analysis
The association of PIM1 expression with clinicopathological characteristics was analyzed using Spearman's correlation analysis. Comparisons were undertaken using one-way ANOVA followed by Dunnett's t-test. The statistical analysis of all data was carried out using SPSS software (SPSS, Chicago, IL, USA). P < .05 was considered statistically significant. (Table 1 ). In contrast, the protein expression of PIM1 was not associated with sex, age, or tumor focus size (Table 1) . Collectively, our results suggested the role of PIM1 as oncogenic factor in CRC. and MMP-9 was also decreased in a concentration-dependent manner ( Figure 4E ).
| PIM1 mediates the antitumor activity of hispidulin in CRC cells
The function of JAK2/STAT3 as an upstream signaling regulator of PIM1 expression has also been reported. 30, 31 In addition, our previous study showed that hispidulin functioned as an inhibitor of STAT3 signaling. 21, 32 Therefore, we hypothesized that hispidulin exerted an antitumor effect by regulating PIM1 through inhibiting JAK2/STAT3. As shown in Figure 5A by hispidulin ( Figure 7D,E) . Therefore, our results revealed that hispidulin exerted an anti-tumor effect by targeting PIM1 through ROS and JAK2/STAT3 signaling.
| Hispidulin suppresses CRC tumor growth and pulmonary metastasis
Based on the results of our in vitro studies, a mouse model was used to evaluate the antitumor in vivo effect of hispidulin. As Figure 8A shows, hispidulin at a dosage of 20 mg/kg could exert significant suppression on tumor growth (P < .01 vs control). Tumor weight was dose-dependently decreased by hispidulin treatment ( Figure 8B ).
In addition, our results showed that hispidulin at both doses did not cause marked change in the body weight of model animals, suggesting the selective toxicity of hispidulin against tumors. Moreover, H&E examination of brain, lung, heart, spleen, kidney, and liver
showed that hispidulin at 40 mg/kg did not cause changes in the morphology of these tissue ( Figure S2 ), further supporting that hispidulin did not damage the healthy tissues. In line with the findings of tumor growth, the TUNEL assay showed that treatment with hispidulin was associated with dose-dependent increases in apoptosis ( Figure 8C ). Immunohistochemistry results showed that hispidulin treatment resulted in decreased levels of PIM1, p-STAT3, and p-JAK2, thus, further supporting our findings in vitro ( Figure 8C ). Hispidulin has been confirmed to affect lung metastasis. As shown in Figure 8D , the number of metastatic nodules in the lungs of mice was significantly decreased by hispidulin treatment. Therefore, our in vivo studies indicated that hispidulin can significantly inhibit cell growth and metastasis in CRC.
| DISCUSSION
It has been reported by Verbeek et al that PIM1 inhibited the apoptosis induced by myc in mouse models of lymphoma. 35 It also has been proven that PIM1 is involved in the development and progression of several solid tumors, including CRC. 12 Of interest, PIM1 inhibitors have been investigated for their efficacy in treating malignancies. For instance, AZD1208 is an effective and selective pan-Pim kinase inhibitor, and has been found to have a good
Oncogenic role of PIM1 in colorectal cancer. A, Knockdown of PIM1 in HT29 and SW480 cells using siRNA. B-F, Effect of PIM1 knockdown on cell growth (B), apoptosis (C), activation of caspase-3 and poly(ADP-ribose) polymerase (PARP) (D), cell invasion (E), and expression of MMP-2 and MMP-9 (F). *P < .05; **P < .01
efficacy in preclinical models of acute myeloid leukemia. 36 AZD1208
has also been found to treat MYC-driven prostate cancers in animal models. 37 Moreover, the pivotal role of PIM kinases in hematopoietic tumors has promoted the development of various pan-PIM inhibitors. For example, this involves phase I trials in patients with relapsed and/or refractory multiple myeloma, and in phase Ib/II trials (CLGH447X2103C, NCT02144038, and EudraCT2013-004959-21)
for patients with relapsed/refractory acute myeloid leukemia who have a high risk of myelodysplastic syndrome and myelofibrosis. 38, 39 Given that PIM1 is constitutively active and not regulated by phosphorylation, 6 modulating the expression of PIM1 at a transcriptional level provides a novel insight for cancer therapy. In the present study, our findings indicated that PIM1 functioned as an oncogene in CRC, and hispidulin suppressed tumor growth and metastasis of CRC through modulating PIM1 expression.
An aberrant upregulation of PIM1 has been documented in solid tumors and hematological malignancies. 8 The role of PIM1 as a prognostic marker has also been examined. For instance, overexpression of the PIM1 protein was associated with the tumorigenesis and lymphatic metastasis of esophageal squamous cell carcinoma. 40 In breast cancer, PIM1 expression was higher in triple-negative tumors than in receptor-positive tumors, and was associated with poor prognosis in patients with hormone-and human epidermal growth factor receptor 2-negative tumors. 41 However, high levels of PIM1 are associated with a good prognosis in prostate cancer, 9 pancreatic ductal carcinoma, 10 and nonsmall-cell lung cancer. 11 In terms of CRC, previous studies have shown a total PIM1 score that reflected the expression of PIM1 in tumors, tumor stroma, and tumor-adjacent mucosa, and has been found to correlate with disease stage; thus, it can be considered a useful prognostic marker for CRC. 12 Interestingly, Peng et al did not observe any correlation between PIM1 expression in tumor tissues and the clinicopathological features of patients.
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On the contrary, our findings revealed a positive association in metastatic behavior. [43] [44] [45] Consistent with these studies, our findings indicated that knockdown of PIM1 using siRNA led to increased apoptotic cell populations and decreased cell motility.
Our findings also indicated that repressing PIM1 expression by hispidulin led to the suppression of cell growth, induction of apoptosis, and inhibition of migration and invasion, all of which provided strong evidence for the role of PIM1 as an oncogenic factor in CRC. In addition to cell apoptosis and invasive behavior, PIM1 has been found to regulate the energy metabolic process of glioma and hepatocellular carcinoma cells. 28, 44 Santio et al have also reported that PIM1 promotes angiogenesis and lymphangiogenesis in orthotopic xenografts of pancreatic cancer. 46 Gu et al have revealed that suppressing PIM1 reduced hypoxia-induced autophagy and enhanced the radiosensitivity of prostate cancer cells. 47 In addition, PIM1 was observed to induce chemoresistance in cancer cells by interaction with phosphorylation of Etk, fms-like tyrosine kinase 3, breast cancer-resistant protein, and P-glycoprotein. 48 Given that hispidulin can modulate the expression of PIM1, hispidulin could affect angiogenesis, autophagy, and glycolysis, all of which could contribute to its antitumor activity. 
